Rivaroxaban Tablet, Film Coated
Product Images NDC 68180-709

This text provides information on Population Description PK Fold Change and 90% CI for various conditions such as End-Stage Renal Disease, Renal Impairment, Age, Body Weight, and Hepatic Impairment. The data includes comparisons between different groups (e.g., Normal vs. Severe, Moderate) and criteria like Creatinine clearance for specific ranges. It also mentions the use of rivaroxaban in ESRD subjects undergoing hemodialysis.*

This text provides information on the drug interactions and the fold change in pharmacokinetics (PK) along with the 90% confidence interval. It includes details on combined P-glycoprotein (P-gp) and strong CYP3A4 inhibitors (such as Ketoconazole, Ritonavir, and Clarithromycin), moderate CYP3A4 inhibitors (including Erythromycin and Fluconazole), strong CYP3A4 inducers (like Rifampicin), and other drugs (like Aspirin, Atorvastatin, Digoxin, and Warfarin). The data presented seems to focus on the impact of these interactions on parameters such as Cmax (maximum concentration) and AUC (area under the curve) for various medications.*

This text appears to contain data related to the evaluation of a medical study comparing the medication Rivaroxaban to a placebo in different age groups, genders, regions, weights, kidney functions, and medical histories. It also includes the efficacy outcomes in terms of a composite measure of stroke, heart attack, or vascular death. The results are presented in percentages and hazard ratios. The study seems to have assessed various factors such as sex, age, weight, kidney function, stroke history, heart failure history, prior diabetes, and peripheral artery disease. Overall, the findings suggest a comparison between Rivaroxaban and the placebo in different subgroups based on the specified parameters.*

This is a comparison of the cumulative incidence rate between Rivaroxaban and Placebo over time. The data includes the number of subjects at risk for each treatment group at different timepoints (days from randomization). Rivaroxaban showed a decrease in incidence rate compared to Placebo.*

This text appears to be a table containing different percentages and outcomes related to a study, such as primary efficacy outcomes, gender distribution (male vs. female), weight categories, baseline diabetes status, randomization strata, use of clopidogrel, history of revascularization, and various numerical data related to Rivarozaban and Placebo. The table also includes statistics such as HR (Hazard Ratios) with their corresponding 95% confidence intervals. The information is likely from a clinical trial or medical study evaluating the effectiveness of different treatments in patients with specific conditions.*

This is a description for Rivaroxaban tablets, containing 2.5mg of Rivaroxaban USP in each tablet. The usual dosage information should be referred to in the accompanying prescribing information. The tablets should be stored at room temperature with excursions permitted within a certain range. The medication guide should be dispensed to each patient and kept out of reach of children. The tablets are manufactured by Lupin Pharmaceuticals in India.*

This is a description for Rivaroxaban tablets, sized 50x18mm, with 30 tablets in the pack. They are USP approved and should be stored at or below 25°C (77°F). The product is manufactured by Lupin Pharmaceuticals, Inc. in India. The medication guide should be dispensed to each patient, and the tablets should be kept out of reach of children.*